Bernstein on Sun Pharma
O-P, TP Rs 2235
Sun Pharmaceutical became sole Indian co among nine drugmakers signing Most-Favored-Nation (MFN) pricing agreements at White House & remains only Indian innovator across all MFN signatories to date.
Believe agreement is strategically important because it both protects & expands Sun's US$1.2-1.3bn innovative-medicines franchise
Under agreement, Sun will extend MFN pricing to participating Medicaid programs and apply MFN principles to future innovative launches
Believe Lower Medicaid net prices could expand patient access, reduce prior-authorization barriers and support broader biologic adoption.
1September 3, 2026 469
